Compare Costco Wholesale Corporation (COST) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Twist Bioscience Corp — how do they compare? Costco Wholesale Corporation trades at $946.92 (market cap $420.05B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Costco Wholesale Corporation is far larger — about 41.7× Twist Bioscience Corp's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Costco Wholesale Corporation for 133 Days and Twist Bioscience Corp for 27 Days on average.
| COST | TWST | |
|---|---|---|
Market Cap | $420.05B | $10.08B |
Volume | 2,087,565 | 4,229,037 |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $205.00 |
52-Week Low | $849.63 | $25.45 |
Typical Hold Time | 133 Days | 27 Days |
Enterprise Value | $407.33B | $10.01B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COST trades at $946.92, up 0.5% today, near its pivot point of $947. The stock shows a bullish technical trend with strong moving averages, though oscillators indicate overbought conditions. Fundamentally, revenue grew to $275.24B in 2025 with a net income margin of 3.04%, while the P/E ratio of 45.66 reflects a premium valuation. Recent news highlights strong March sales growth of 11.3% year-over-year and a membership fee increase, signaling pricing power.
The outlook remains positive with analyst consensus strongly favoring Buy (66.1%) and a price target of $1,100, implying ~16% upside. Key risks include high valuation sensitivity and competitive pressures. Earnings growth and membership renewal rates are critical catalysts for sustained appreciation, but any miss could trigger a pullback.
Twist Bioscience (TWST) trades at $159.78, up 2.65% today, showing strong momentum despite mixed technical signals. The company continues to demonstrate robust revenue growth, with 2025 revenue reaching $377 million, though profitability remains elusive with a -31.66% net income margin. Recent positive developments include a strategic partnership with Eli Lilly's TuneLab AI platform announced September 16, 2026, driving investor optimism about the company's AI-driven drug discovery capabilities.
While analyst consensus remains bullish with 73% buy ratings, the stock faces significant fundamental challenges including persistent cash burn and negative earnings. The current price exceeds the $145.20 consensus target, suggesting limited near-term upside. Key risks include execution challenges in achieving profitability and dependence on AI partnerships for growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
